Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorUniversitaire Ziekenhuizen KU Leuven

About this trial

This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.

Eligibility criteria

Qualifiers

all patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven and who give informed consent

Disqualifiers

age under 18 years

Trial design

Treatments tested in this trial

  • SARS-CoV-2 IgG

Treatment groups

2,000 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Universitaire Ziekenhuizen KU Leuven

Lead sponsor

KU Leuven

Collaborator

Hasselt University

Collaborator

Ziekenhuis Oost-Limburg

Collaborator

Jessa Hospital

Collaborator